Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $30.00.

Yi Chen has given his Buy rating due to a combination of factors, most notably the advancing late-stage development of DURAVYU for wet age-related macular degeneration (AMD), where two pivotal Phase 3 studies are proceeding on schedule toward topline data in mid-2026 and have so far shown safety consistent with earlier trials. He also emphasizes that these trials were designed in close alignment with both U.S. and European regulators, and that the large, predominantly treatment-naïve patient population could support a compelling efficacy and market-access narrative if non-inferiority versus aflibercept is achieved.

Chen’s rating is based on the view that DURAVYU has significant commercial potential across both wet AMD and diabetic macular edema (DME), supported by an expanding Phase 3 DME program that targets key disease pathways and is expected to fully enroll by 3Q26, with data in 4Q27. He further highlights EyePoint’s cash balance of about $222.5M, which is projected to fund operations into 4Q27, and underpins a discounted cash flow valuation that, incorporating probability-adjusted success in both indications and current cash, supports maintaining an unchanged 12‑month price target of $30 per share.

According to TipRanks, Chen is a 2-star analyst with an average return of 0.5% and a 41.50% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Opko Health, and CareDx.

In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $29.00 price target.